You are here: Industry Insights > RegeneRx

News List

RegeneRx Biopharmaceuticals Announces $2 Million Private Placement firstwordpharma
June 29, 2021
RegeneRx Biopharmaceu today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to $2,000,000.
ARISE-3 Dry Eye Trial Does Not Meet Primary Outcome Measures americanpharmaceuticalreview
March 24, 2021
RegeneRx Biopharmaceuticals announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome did not meet its primary outcome measures.
RegeneRx Joint Venture Announces Neurotrophic Keratopathy Trial Results americanpharmaceuticalreview
May 20, 2020
ReGenTree and RegeneRx Biopharmaceuticals announced the results of a randomized, double masked, placebo-controlled Phase 3 clinical trial (SEER-1) using RGN-259 for the treatment of neurotrophic keratopathy (NK).
RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259 pharmafocusasia
February 14, 2019
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration....
RegeneRx Secures $1 Million in Funding biospace
March 05, 2018
RegeneRx Biopharmaceuticals, Inc. today announced that it entered into a Warrant Reprice Agreement whereby it received $1.03 million in warrant exercise proceeds.